At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Concurrent Radiation Therapy, Temozolomide, and Bevacizumab Followed by Bevacizumab/Everolimus in the First-line of Treatment of Patients With Glioblastoma Multiforme
In Brief
A Phase 2 clinical trial evaluating Radiation therapy, Temozolomide, and 2 other interventions for Glioblastoma Multiforme. Completed, enrolled 68 participants across 13 sites.
Detailed Summary
In this phase II trial the investigators plan to incorporate two targeted agents, bevacizumab and everolimus, into the first-line multimodality therapy of glioblastoma. In the first portion of the treatment, bevacizumab will be added to standard concurrent radiation therapy plus temozolomide. After completing radiation therapy, patients will continue treatment with the combination of bevacizumab and everolimus.
Study Details
Timeline
Interventions
Radiation therapy, 2.0 Gy daily, 5 days per week by single daily dose, to a total of 60 Gy over 6 weeks
Temozolomide 75mg/m2 by mouth daily, beginning day 1 of radiation therapy and continuing through the last day of radiation therapy
Bevacizumab 10mg/kg IV, every 2 weeks, beginning day 1 of radiation therapy
Bevacizumab 10mg/kg IV, every 2 weeks, beginning Week 11
Everolimus 10mg by mouth daily, beginning Week 11